Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $50,660.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 2,000 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $25.33, for a total value of $50,660.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total transaction of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.53, for a total transaction of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $26.68, for a total value of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.07, for a total transaction of $75,210.00.

Enliven Therapeutics Stock Performance

ELVN opened at $25.51 on Friday. The company has a market cap of $1.20 billion, a PE ratio of -13.22 and a beta of 1.09. The stock has a 50-day moving average of $23.20 and a 200-day moving average of $21.86. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, research analysts predict that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Analyst Ratings Changes

ELVN has been the topic of several research reports. Robert W. Baird began coverage on Enliven Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday. Finally, Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th.

Institutional Trading of Enliven Therapeutics

Large investors have recently modified their holdings of the company. Quest Partners LLC lifted its position in Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares during the period. EntryPoint Capital LLC acquired a new position in shares of Enliven Therapeutics during the 1st quarter worth about $167,000. SG Americas Securities LLC bought a new stake in Enliven Therapeutics during the 3rd quarter valued at approximately $256,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at approximately $322,000. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.